miR‑139‑3p suppresses the invasion and migration properties of breast cancer cells by targeting RAB1A

Zhang,Wei; Xu,Jing; Wang,Ke; Tang,Xiaojiang; He,Jianjun

doi:10.3892/or.2019.7297

miR‑139‑3p suppresses the invasion and migration properties of breast cancer cells by targeting RAB1A

Authors:
- Wei Zhang
- Jing Xu
- Ke Wang
- Xiaojiang Tang
- Jianjun He
View Affiliations

Affiliations: Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: August 29, 2019 https://doi.org/10.3892/or.2019.7297
Pages: 1699-1708
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Accumulated evidence indicates that aberrant microRNAs (miRNAs) expression plays an important role in the initiation and progression of various cancers, including breast cancer. Previous studies suggested that miR‑139‑3p might serve as a tumor suppressor and is downregulated in several cancer types. However, the expression patterns and exact role of miR‑139‑3p in breast cancer remain to be elucidated. In this study, we aimed to analyze the effect of miR‑139‑3p on the progression of breast cancer and the mechanism involved. Through bioinformatics analysis and in vitro experimental studies, we found that miR‑139‑3p was decreased in breast cancer tissues and cell lines, and decreased miR‑139‑3p is associated with a poor prognosis in breast cancer patients. Overexpression of miR‑139‑3p by transfection significantly inhibits cell proliferation, migration, and invasion of breast cancer cells. Bioinformatics analysis and luciferase reporter gene assay confirmed that RAB1A was a potential target of miR‑139‑3p. Furthermore, overexpression of RAB1A counteracted the suppressing effects of miR‑139‑3p on breast cancer cell migration, invasion and epithelial‑to‑mesenchymal transition (EMT). Taken together, these data suggest that miR‑139‑3p plays a tumor suppressive role in breast cancer by targeting RAB1A and may serve as a potential new biomarker for breast cancer prognosis.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
2	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
3	Wang Y and Zhou BP: Epithelial-mesenchymal transition in breast cancer progression and metastasis. Chin J Cancer. 30:603–611. 2011. View Article : Google Scholar : PubMed/NCBI
4	van Zijl F, Krupitza G and Mikulits W: Initial steps of metastasis: Cell invasion and endothelial transmigration. Mutat Res. 728:23–34. 2011. View Article : Google Scholar : PubMed/NCBI
5	Chambers AF, Groom AC and MacDonald IC: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2:563–572. 2002. View Article : Google Scholar : PubMed/NCBI
6	Abak A, Amini S, Sakhinia E and Abhari A: MicroRNA-221: Biogenesis, function and signatures in human cancers. Eur Rev Med Pharmacol Sci. 22:3094–3117. 2018.PubMed/NCBI
7	Ardekani AM and Naeini MM: The Role of MicroRNAs in human diseases. Avicenna J Med Biotechnol. 2:161–179. 2010.PubMed/NCBI
8	Ullah S, John P and Bhatti A: MicroRNAs with a role in gene regulation and in human diseases. Mol Biol Rep. 41:225–232. 2014. View Article : Google Scholar : PubMed/NCBI
9	Tüfekci KU, Oner MG, Meuwissen RL and Genc S: The role of microRNAs in human diseases. Methods Mol Biol. 1107:33–50. 2014. View Article : Google Scholar : PubMed/NCBI
10	Waldman SA and Terzic A: Applications of microRNA in cancer: Exploring the advantages of miRNA. Clin Transl Sci. 2:248–249. 2009. View Article : Google Scholar : PubMed/NCBI
11	Reddy KB: MicroRNA (miRNA) in cancer. Cancer Cell Int. 15:382015. View Article : Google Scholar : PubMed/NCBI
12	Lee YS and Dutta A: MicroRNAs in cancer. Annu Rev Pathol. 4:199–227. 2009. View Article : Google Scholar : PubMed/NCBI
13	Chen L, Li Y, Fu Y, Peng J, Mo MH, Stamatakos M, Teal CB, Brem RF, Stojadinovic A, Grinkemeyer M, et al: Role of deregulated microRNAs in breast cancer progression using FFPE tissue. PLoS One. 8:e542132013. View Article : Google Scholar : PubMed/NCBI
14	Wang B, Li J, Sun M, Sun L and Zhang X: miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features. IUBMB Life. 66:371–377. 2014. View Article : Google Scholar : PubMed/NCBI
15	Tang J, Ahmad A and Sarkar FH: The role of microRNAs in breast cancer migration, invasion and metastasis. Int J Mol Sci. 13:13414–13437. 2012. View Article : Google Scholar : PubMed/NCBI
16	van Schooneveld E, Wildiers H, Vergote I, Vermeulen PB, Dirix LY and Van Laere SJ: Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. Breast Cancer Res. 17:212015. View Article : Google Scholar : PubMed/NCBI
17	Ng L, Wan TM, Man JH, Chow AK, Iyer D, Chen G, Yau TC, Lo OS, Foo DC, Poon JT, et al: Identification of serum miR-139-3p as a non-invasive biomarker for colorectal cancer. Oncotarget. 8:27393–27400. 2017. View Article : Google Scholar : PubMed/NCBI
18	Liu X, Duan B, Dong Y, He C, Zhou H, Sheng H, Gao H and Zhang X: MicroRNA-139-3p indicates a poor prognosis of colon cancer. Int J Clin Exp Pathol. 7:8046–8052. 2014.PubMed/NCBI
19	Yonemori M, Seki N, Yoshino H, Matsushita R, Miyamoto K, Nakagawa M and Enokida H: Dual tumor-suppressors miR-139-5p and miR-139-3p targeting matrix metalloprotease 11 in bladder cancer. Cancer Sci. 107:1233–1242. 2016. View Article : Google Scholar : PubMed/NCBI
20	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
21	Lee JA, Lee HY, Lee ES, Kim I and Bae JW: Prognostic implications of MicroRNA-21 overexpression in invasive ductal carcinomas of the breast. J Breast Cancer. 14:269–275. 2011. View Article : Google Scholar : PubMed/NCBI
22	Zhai J, Yang X, Zhang Y, Qi Q, Hu J and Wang Q: Reduced expression levels of the death-associated protein kinase and E-cadherin are correlated with the development of esophageal squamous cell carcinoma. Exp Ther Med. 5:972–976. 2013. View Article : Google Scholar : PubMed/NCBI
23	Lánczky A, Nagy Á, Bottai G, Munkácsy G, Szabó A, Santarpia L and Győrffy B: miRpower: A web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer Res Treat. 160:439–446. 2016. View Article : Google Scholar : PubMed/NCBI
24	Dongre A, Rashidian M, Reinhardt F, Bagnato A, Keckesova Z, Ploegh HL and Weinberg RA: Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas. Cancer Res. 77:3982–3989. 2017. View Article : Google Scholar : PubMed/NCBI
25	Bill R and Christofori G: The relevance of EMT in breast cancer metastasis: Correlation or causality. FEBS Lett. 589:1577–1587. 2015. View Article : Google Scholar : PubMed/NCBI
26	Sannigrahi MK, Sharma R, Singh V, Panda NK, Rattan V and Khullar M: Role of host miRNA Hsa-miR-139-3p in HPV-16-induced carcinomas. Clin Cancer Res. 23:3884–3895. 2017. View Article : Google Scholar : PubMed/NCBI
27	Huang P, Xi J and Liu S: miR-139-3p induces cell apoptosis and inhibits metastasis of cervical cancer by targeting NOB1. Biomed Pharmacother. 83:850–856. 2016. View Article : Google Scholar : PubMed/NCBI
28	Jin M, Saucan L, Farquhar MG and Palade GE: Rab1a and multiple other Rab proteins are associated with the transcytotic pathway in rat liver. J Biol Chem. 271:30105–30113. 1996. View Article : Google Scholar : PubMed/NCBI
29	Tanaka M, Mun S, Harada A, Ohkawa Y, Inagaki A, Sano S, Takahashi K, Izumi Y, Osada-Oka M, Wanibuchi H, et al: Hsc70 contributes to cancer cell survival by preventing Rab1A degradation under stress conditions. PLoS One. 9:e967852014. View Article : Google Scholar : PubMed/NCBI
30	Thomas JD, Zhang YJ, Wei YH, Cho JH, Morris LE, Wang HY and Zheng XFS: Rab1A is an mTORC1 activator and a colorectal oncogene. Cancer Cell. 30:181–182. 2016. View Article : Google Scholar : PubMed/NCBI
31	Wang X, Liu F, Qin X, Huang T, Huang B, Zhang Y and Jiang B: Expression of Rab1A is upregulated in human lung cancer and associated with tumor size and T stage. Aging (Albany NY). 8:2790–2798. 2016. View Article : Google Scholar : PubMed/NCBI
32	Xu H, Qian M, Zhao B, Wu C, Maskey N, Song H, Li D, Song J, Hua K and Fang L: Inhibition of RAB1A suppresses epithelial-mesenchymal transition and proliferation of triple-negative breast cancer cells. Oncol Rep. 37:1619–1626. 2017. View Article : Google Scholar : PubMed/NCBI
33	Shimada K, Uzawa K, Kato M, Endo Y, Shiiba M, Bukawa H, Yokoe H, Seki N and Tanzawa H: Aberrant expression of RAB1A in human tongue cancer. Br J Cancer. 92:1915–1921. 2005. View Article : Google Scholar : PubMed/NCBI